Joseph Araujo, President and CEO

As President and CEO, Joseph is focused on optimizing the translational value of InterVivo's services to facilitate the development and approval of novel drugs. Joseph continues to be closely involved in projects utilizing, characterizing and developing the aged dog as a natural model of age-related human diseases. Joseph is a strong proponent for the use of validated natural and/or translational animal models in drug discovery. His scientific background includes graduate training in pharmacology at the University of Toronto, more than 25 refereed publications and several invited presentations, which exemplifies his continued passion for scientific innovation and expertise in natural aged canine models of human disease. Joseph directly supports developing of local biotech talent and companies and has co-founded and held executive level positions in several Ontario-based Contract Research and Life Science companies helping to build their global presence and success.

Guy Higgins, Chief Scientific Officer

As the Chief Scientific Officer of InterVivo, Guy brings over 20 years International CNS Research and Development experience with major BioPharma organizations such as Glaxo-Wellcome, Hoffmann-La Roche, Schering Plough and NPS Pharmaceuticals. As a leader of functional CNS groups in most of these organizations, Guy has demonstrated a sustained commitment to the development and implementation of translational animal models to support the identification and progression of novel chemical entities from early discovery through to clinical development. It is this experience and background that has allowed Guy, together with Joseph, to forge the vision of IVS and its service offerings. Guy has co-authored over 120 research papers and review articles covering aspects of CNS pharmacology, drug discovery and behavioural neuroscience. Guy received his PhD in 1990 and currently holds the position of Adjunct Professor in the Pharmacology department at the University of Toronto.

David K.H. Lee, Ph.D., Executive Vice President, Scientific Affairs

As the Executive Vice President, Scientific Affairs, David's responsibility is to grow the company and to add value for the stakeholders. He will accomplish this by promoting InterVivo Solutions' broad range of offerings focusing on CNS therapeutics, and by searching, evaluating and partnering complementary innovative technologies that will benefit both companies. David brings with him over 35 years of pharmaceutical industry experience having worked with increasing executive responsibilities through Pfizer (formerly Wyeth Laboratories), Johnson and Johnson, Allelix Biopharmaceutical (later became NPS Pharmaceuticals), and most recently NoAb BioDiscoveries.

Inés de Lannoy, Ph.D., Vice President, Research and Development

As Vice President of Research and Development, Inés brings both pharmacokinetics (PK) and drug discovery experience to IVS, having worked at a number of biopharmaceutical and contract research organizations (CROs) over the past 18 years. She was responsible in her previous role at two CROs, for building the in vivo PK, in vitro ADME, high throughput screening and bioanalytical capabilities of the companies, for offering as a service to pharmaceutical clients. While at Allelix Biopharmaceuticals (now NPS Pharmaceuticals), she advanced several drug candidates from discovery into clinical trials. Inés strives to develop new pre-clinical models/methods for the more accurate and facile characterization of human PK. Her expertise in the transport of xenobiotics across the blood-brain barrier, an area in which she has a keen research interest, is a valuable asset to IVS clients. Inés obtained a Ph.D. in drug and metabolite PK from the University of Toronto (1990) and currently holds the position of Adjunct Professor in Chemistry at the University of Waterloo and Assistant Professor (status only) in the Leslie Dan Faculty of Pharmacy at the University of Toronto. She also serves on the editorial boards of Biochemical Pharmacology and Biopharmaceutics and Drug Disposition.

Sal Lemus, Director of Sales and Marketing

As the Director of Sales and Marketing, Sal's role is focused on keeping our sponsors aware of the exciting developments at InterVivo. Sal provides day-to-day leadership for the sales and marketing efforts of the company and is a constant advocate for ways of better serving InterVivo's sponsors and partners. He is passionate about new developments in drug discovery research and has worked for over 10 years in a marketing and business development capacity for innovative Contract Research Organizations. His passion for connecting the world between science and business is evidenced by his career as well as his education, having graduated from the University of Waterloo with a Hon. B.Sc. Biotechnology/Economics.